注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Plus Therapeutics Inc是一家臨床階段的製藥公司。該公司專注於開發癌症患者診療方案。該公司提供納米技術平台來重新制定和改進主管化學治療方法,使患者和醫療保健提供者受益。該公司專注於開發非專利腫瘤藥物,以解決未滿足的醫療和市場需求。該公司的候選鉛產品DocePlus是一種白蛋白穩定的聚乙二醇化多西紫杉醇脂質體製劑,開髮用於治療小細胞肺癌(SCLC)。該公司還開發了DoxoPLUS,一種非專利的聚乙二醇化脂質體製劑,開髮用於治療乳腺癌、卵巢癌,多發性骨髓瘤和Kaposi的肉瘤。該公司還專注於開發Rhenium-186 NanoLiposome(186RNL),用於治療復發性膠質母細胞瘤,以及罕見和致命疾病。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Richard J. Hawkins | 72 | 2007 | Independent Chairman of the Board |
Robert P. Lenk | 73 | 2020 | Independent Director |
Vladimir P. Torchilin | 74 | 2020 | Member of Scientific Advisory Board |
John C. McKew | 57 | 2020 | Member of Scientific Advisory Board |
Andrew J. Brenner | - | 2020 | Member of Scientific Advisory Board |
Marc H. Hedrick | 58 | 2002 | President, CEO & Director |
An van Es-Johansson | 61 | 2020 | Independent Director |
Howard Clowes | 67 | 2020 | Independent Director |
Michael Vogelbaum | - | 2020 | Member of Clinical Advisory Board |
Gregory B. Petersen | 58 | 2020 | Independent Director |
Nicholas Butowski | - | 2020 | Member of Clinical Advisory Board |
Manish Aghi | - | 2020 | Member of Clinical Advisory Board |
Alireza Mohammadi | - | 2020 | Member of Clinical Advisory Board |
Russell Lonser | - | 2020 | Member of Clinical Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核